A REVIEW ON ESSENTIAL DOSING AND PRESCRIBING DOSE FOR ZIHERA

Abstract

ZIIHERA (zanidatamab-hrii) is a bispecific human epidermal growth factor receptor 2 (HER2)-directed antibody indicated for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. The therapeutic administration involves intravenous (IV) infusion, commonly given on a biweekly schedule until disease progression or unacceptable toxicity occurs. To mitigate the risk of infusion-related reactions (IRRs), mandatory premedication with an antipyretic, an antihistamine, and a corticosteroid must be administered 30 to 60 minutes prior to every infusion.The initial two infusions are administered over a specific duration. If well-tolerated, the duration can be reduced for subsequent administrations. Safety profiles require monitoring for left ventricular dysfunction (LVD) and severe diarrhea. Dosage modifications for adverse events may be required, or permanent treatment discontinuation for unmanaged toxicities.

Keywords